LeMaitre Vascular (LMAT) Scheduled to Post Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of $0.44 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The firm had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same period last year, the firm earned $0.37 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Price Performance

LMAT opened at $90.41 on Wednesday. LeMaitre Vascular has a fifty-two week low of $45.96 and a fifty-two week high of $93.32. The firm has a market capitalization of $2.03 billion, a PE ratio of 59.87, a P/E/G ratio of 2.29 and a beta of 0.88. The company’s 50-day moving average is $89.33 and its 200 day moving average is $82.50.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Analyst Ratings Changes

LMAT has been the subject of a number of analyst reports. Barrington Research reissued an “outperform” rating and issued a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. JMP Securities increased their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $94.67.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.